Research programme: antibacterials - ImmuPharma

Drug Profile

Research programme: antibacterials - ImmuPharma

Alternative Names: IPP-203101

Latest Information Update: 12 Jun 2014

Price : $50

At a glance

  • Originator ImmuPharma
  • Developer CNRS; ImmuPharma
  • Class Peptides
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Methicillin-resistant Staphylococcus aureus infections; Nosocomial infections

Most Recent Events

  • 12 Jun 2014 Preclinical development for Methicillin-resistant Staphylococcus aureus infections is still ongoing in France
  • 05 Apr 2011 Preclinical development is ongoing in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top